Hualan Biological Engineering, Inc.
华兰生物
002007
Shenzhen Stock Exchange
Company Profile
Hualan Bio is the first company whose plasma products gain GMP certificate in China. The plasma products of Hualan Bio contain three classifications, albumin, immunoglobulin and coagulation factors, with 11 products of 34 specifications in total. Hualan Bio is one of few domestic plasma products manufacturers that can extract six compositions from plasma, as well as one of the companies owning most complete types of coagualtion factor products in the same industry in China. Currently, the production scale, specifications, market share, production and sales amount of leading products of Hualan are on the top in the same industry in China. Hualan Bio is also one of the largest manufacturer of Influenza Vaccine (Split virion), Inactivated in China now. In June 2009, Hualan Bio developed the first Influenza A (H1N1) Vaccine (Split, Inactivated) in the world and undertook nearly 40% of Chinese reserve tasks, providing strong support for the prevention and control of Influenza A epidemic in China. The shareholding subsidiary of Hualan formally marched into the fields of genic recombination and monoclonal antibody in 2013. At present, a number of clinical trials of multiple monoclonal antibody drugs are being conducted.Therefore, based on plasma products, the company develops product portfolio of diversity to further strengthen the dominant position of plasma products; expands the scale of vaccine industry quickly; and develops recombinant hormone drugs and antibody drugs vigorously; what’s more, Hualan expands strategic cooperation with domestic and foreign competitive enterprises; cultivate new profit growth point; enhance the company's core competitiveness. The large biological industry pattern with the core of plasma products, vaccines, monoclonal antibodies and recombinant drugs is gradually formed; clear development strategy in the future ensures the company's sustained and healthy development. Hualan Bio values the return to investors, and the cumulative cash bonus is 2.031 billion RMB from listing.
Full description
Founded in 1992, Hualan Bio is a national high-tech enterprise which engages in the production, R&D and marketing of plasma products, vaccines, and genetic engineering products, one of the largest manufacturing enterprises of plasma products and influenza vaccines in China, with registered capital of RMB 930.0876 million. Hualan Bio is the birthplace of the first H1N1 Influenza Vaccine in the whole world; the first enterprise whose Influenza Vaccine (Split, Virion), Inactivated passes WHO-PQ in China; the first company whose plasma products gain GMP certificate in China; whose property is throughout Henan, Chongqing, Beijing and other 6 provinces and cities, and owns 30 subsidiaries. Passing "ISO" management system certifications of quality, environment and occupational health, the company has a number of independent intellectual property rights, and trademark of “Hualan” is recognized as Chinese well-known trademark. With the features of production scale, various specifications, market share, brand influence and so on, the leading products guide domestic development of the industry.The main business of Hualan Bio are plasma products and vaccine products, while the plasma products include Human Albumin, Human Immunoglobulin (pH4) for Intravenous Injection, Human Prothrombin Complex, Human Coagulation Factor VIII and other 11 varieties (34 specifications). The company is one of the highest comprehensive utilization rates of plasma, the most varieties and the most complete specifications of enterprises among the plasma products industry in China. Hualan Biological Bacterin Co., Ltd, as a holding subsidiary of Hualan Bio, engages in R&D, production and marketing of vaccines. Currently, Influenza Vaccine (Split virion), Inactivated, Influenza A (H1N1) Vaccine (Split, Inactivated), Group ACYW135 Meningococcal Polysaccharide Vaccine and Recombinant Hepatitis B Vaccine (Hansenula polymorph) have been on the market. While at the same time, Enterovirus Type 71 Vaccine, Inactivated, Nasal Spray Type Influenza Vaccine, Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, Adsorbed, QIV, Pneumococcal Vaccine Polyvalent, Therapeutic Hepatitis B Vaccine and other several items are under R&D. Hualan Genetic Engineering Co., Ltd, as a shareholding company of Hualan Bio, researches, develops and produces monoclonal antibody drugs, and has obtained the clinical trial approvals for Trastuzumab, Rituximab, Bevacizumab and Adalimumab. Clinical trials are conducted as planned.